Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...
Renal & Urology News

BCR Endpoints an Unreliable Surrogate for Survival in Prostate Cancer Trials

Biochemical recurrence endpoints did not reliably predict overall survival in prostate cancer trials. Treatments that reduce the risk for biochemical recurrence (BCR) do not necessarily improve ...
Business Wire

BCR Announces Major Rebranding Rollout in Coming Months

JACKSONVILLE, Fla.--(BUSINESS WIRE)--BCR today announced it will be rolling out a major repositioning and brand refresh this Spring which parallels a recently announced expansion to provide its ...
ascopubs.org

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia

Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
The American Journal of Managed Care

While Prognostic, BCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival

Measuring biochemical recurrence (BCR) as a surrogate marker produces unreliable results as a primary end point for overall survival of patients with localized prostate cancer, a study found. In a ...
Business Wire

BCR Announces Strategic Partnership to Bring Leading Belt Dryer Brand SEVAR to North American Market

JACKSONVILLE, Fla.--(BUSINESS WIRE)--BCR Inc, a leading provider of proven biosolids and process treatment technology solutions, announced today a strategic partnership with leading Germany-based belt ...